In the year 2020, insulin products worth over INR 3000 crores were sold in India. Over 75% of this insulin was marketed by multinational companies and the remaining one-fourth by Indian companies. However, most of the insulin regardless of who marketed them was manufactured in India. Only a small percentage of newer analogs are currently imported into India.[1]
At any given time in our country, many millions of these insulin vials, prefilled pens, and cartridges are either in transport maintaining the cold chain, in storage in temperature-controlled warehouses, or in monitored and unmonitored pharmacy refrigerators around the country, or placed in unmonitored domestic refrigerators at homes, offices, schools, hospital wards, and clinics, packed into pockets, purses, bags, backpacks, briefcases of patients with diabetes (PwD), stashed in glove compartments of cars and in overhead bins of aircraft and at many times left on dining tables, bedside tables, sideboards, cupboards, kitchens, bathrooms and assorted places in the homes of PwD.
All insulins including analogs insulins are prone to physical and chemical degradation over time which then leads to a corresponding loss of potency. Fluctuations in temperature, exposure to direct sunlight, shearing stress when insulin containers are agitated, and exposure to air with an increased air-liquid surface which happens when there is a decrease in volume because of usage in a vial and inadvertent freezing followed by thawing are the major factors that lead to insulin degradation. The two major chemical pathways for insulin degradation include deamidation and polymerization. Both the deamidated and polymerized insulin metabolites still retain some glucose-lowering potency. In contrast, the primary physical pathway for degradation is the slow aggregation of insulin molecules into fibrils. Stable bonds between insulin molecules within the fibrils prevent their absorption when they are administered subcutaneously. Physical degradation can be confirmed under microscopy but can also be detected by visual inspection of the vial. This is may be more difficult to visualize in newer cartridges and prefilled pens.[2]
The stability of an insulin preparation would be measured by measuring the persisting potency of the preparation over its travel from the manufacturing site to the home of the PwD. In the past potency of insulin were measured using biological assays in rabbit and mice to document glucose-lowering capacity. One unit of insulin historically was the amount of insulin required to produce hypoglycemia (seizures) in an adult rabbit. Today most pharmacopeias recognize high-pressure liquid chromatography (HPLC) as the standard method to assess insulin potency.[3] All insulin manufacturing companies in India have invested in good manufacturing practices to improve the stability of insulin produced at factories and in resources for temperature-controlled transport and storage all along the supply chain till the insulin reaches the pharmacy. Once insulin reaches the pharmacy or the hospital it is supposed to be stored in a temperature-controlled and monitored pharmaceutical refrigerators. A daily documentation of minimum and maximum temperatures is recommended but rarely followed. Supply chain guidelines that are followed and the quality assurance tools for insulin are summarized in Figure 1.[4]
Figure 1: The supply chain from manufacturer to end-user (the person with diabetes) has robust quality assurances (QA) and guidance along the first part of the chain but has sparse guidelines and QA in the second half of the supply chain of insulin. [Abbreviations- WHO- World Health Organization, PwD- Person with Diabetes, HCP- Health Care Professional]
At the end of the supply, chain insulin finds its way to the homes of patients with diabetes or to hospital wards. The limited guidance at this point includes package inserts which in most cases mention that insulin formulations should be stored in a refrigerator between 2-8 degrees and discarded once it is beyond the documented date of expiry. Alternatively, the package inserts mention that insulin can also be stored at room temperatures (15 -30 degrees) provided it is used within a certain time which could range from 14 days (Isophane insulin) to 8 weeks (Insulin Degludec). For most insulin formulations, unused insulin kept at room temperature should be discarded after 28 days.
GUIDELINES ON INSULIN STORAGE AT HOMES OF PATIENTS WITH DIABETES
In this issue of the Journal Pande et al.[5] publish a survey of physicians’ attitudes to alternative strategies for insulin storage in the absence of electricity or refrigeration. The survey was undertaken during a regional diabetes conference and 188 physicians (of whom 93% prescribed insulin) responded to the questionnaire. In absence of refrigeration use of clay pots, icepacks, and thermos flasks were suggested for use at home. For travel purposes, in summer, the use of clay pots, thermos flasks, icepacks, etc., was suggested.[4] However, what was clear from the survey was the lack of clear guidelines for insulin storage at home despite the large number of patients using insulin in our country. A multinational, multicentric study from Africa and South Asia suggested that evaporative devices like clay pots and goat skins could be used in resource-poor countries to keep insulin cool and were effective.[6] However, a recent guideline from the East African Diabetes Study Group discouraged the use of clay pots because of hygiene and contamination issues.[7]
Guidelines are sparse but the available ones are summarized in Table 1.[7–10]
Table 1: Published insulin storage guidance –Similarities and differences
What remains common in all the guidelines is the adherence to the manufacturers’ instructions that unused insulin should be stored in a refrigerator between 2-8 degrees. Most PwDs even in developed countries have household refrigerators at home. These are primarily designed to store food not drugs and are optimized for food safety (0-4 degrees). This is a few degrees below what manufacturers recommend and at the lower end reaches the freezing point. Additionally, unlike pharmaceutical refrigerators, household refrigerators do not have air ventilators to circulate the temperature evenly. This would mean that within the refrigerator there could be areas that approach freezing temperatures even within the regular compartment of the refrigerator. Household refrigerators also show significant day-to-day and hour-to-hour variations in the temperatures maintained inside. In a recent study, Bluetooth-enabled temperature sensors was placed next to insulin stored in household refrigerators by 338 PwDs. Deviations were found in all the sensors placed in the refrigerators with sensors being out of range 11.3% of the time. 17% percent of the sensors revealed excursions below freezing point.[11]
Suggestions from the International Diabetes Federation (IDF) Europe awareness paper for insulin storage include using an airtight container to store insulin within the refrigerator, avoiding small refrigerators including dorm-style and hotel mini-bar refrigerators which tend to freeze more than larger household refrigerators, and keeping a thermometer next to the insulin and regulating the thermostat based on the inputs.[7]
WAY FORWARD
What the current paper exposes is the lack of clarity among HCPs about how they should educate a PwD who is prescribed insulin regarding insulin storage. This is not surprising considering whatever limited guidelines that are available to HCPs are just reflections of the guidance printed by insulin manufacturers in package inserts accompanying the product. The lack of guidelines is also probably a reflection of the fact that there have been limited studies and quality audits on the last and vital leg of the insulin cold chain (storage in the home of PwD) prior to its administration. Since most of our required insulin is manufactured within the country, insulin manufacturing companies should be encouraged to undertake work to improve the science and guidance about insulin storage at the homes of PwDs in all kinds of situations and climates.
REFERENCES
2. Beals JM, DeFelippis MR, Kovach PM, Jackson JA. Insulin Crommelin DJA, Sindelar RD, Meibohm B Pharmaceutical Biotechnology 4 New York Springer 2013.
3. Fisher BV, Smith D. HPLC as a replacement for the animal response assays for insulin. J Pharm Biomed Anal 1986;4:377–87.
4. Heinemann L, Braune K, Carter A, Zayani A, Krämer LA. Insulin storage:A critical reappraisal. J Diabetes Sci Technol 2021;15:147–59.
5. Pande AK, Thakur AK, Kanchan A, Srivastava I. Addressing challenges in insulin storage:An ethical dilemma among physicians. Indian J Endocr Metab 2023;27:140–4.
6. Ogle GD, Abdullah M, Mason D, Januszewski AS, Besançon S. Insulin storage in hot climates without refrigeration:Temperature reduction efficacy of clay pots and other techniques. Diabet Med 2016;33:1544–53.
7. Bahendeka S, Kaushik R, Swai AB, Otieno F, Bajaj S, Kalra S, et al. EADSG guidelines:Insulin storage and optimisation of injection technique in diabetes management. Diabetes Ther 2019;10:341–66.
8. Tandon N, Kalra S, Balhara YPS, Baruah MP, Chadha M, Chandalia HB, et al. Forum for injection technique and therapy expert recommendations, India:The Indian Recommendations for best practice in insulin injection technique, 2017 Indian J Endocrinol Metab 2017;21:600–17.
9. Storage of Insulin- IDF Europe Awareness Paper Available from:
https://idf.org/images/IDF_Europe/Storage_of_Insulin_-_IDF_Europe_Awareness_Paper_-_FINAL.pdf Last accessed on 2023 Apr 04.
10. Danne T, Phillip M, Buckingham BA, Jarosz-Chobot P, Saboo B, Urakami T, et al. ISPAD clinical practice consensus guidelines 2018:Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2018;19 Suppl 27 115–35.
11. Braune K, Kraemer LA, Weinstein J, Zayani A, Heinemann L. Storage conditions of insulin in domestic refrigerators and when carried by patients:Often outside recommended temperature range. Diabetes Technol Ther 2019;21:238–44.